Ipamorelin dosage UK — protocols, reconstitution & handling

Raun et al. (1998) and Gobburu et al. (1999) characterised Ipamorelin's pharmacokinetics in human subjects using intravenous doses of 0.03–3 µg/kg, establishing a clean GH-selective release profile without meaningful cortisol, prolactin or ACTH elevation — the finding Ipamorelin is best known for.

Research protocols in the wider GHRP-mimetic literature typically administer 100–300 mcg subcutaneous per dose, one to three times daily, with doses timed at least 60–90 minutes away from food or sugar so the GH pulse is not blunted. A common research pattern is a morning fasted dose plus a pre-sleep dose to overlap with the natural nocturnal GH pulse.

For the mechanistic pairing rationale see the Ipamorelin vs CJC-1295 comparison and the peptide stacking guide.

Ipamorelin drives a sharp, short GH pulse that peaks within ~30 minutes and returns near baseline by ~2 hours. Elevated glucose or insulin at the moment of administration blunts that pulse — this is why the research literature times doses 60–90 minutes away from meals, ideally fasted.

Common research patterns:

• 1× daily: pre-sleep, on an empty stomach — overlaps with the natural nocturnal GH pulse.
• 2× daily: morning fasted + pre-sleep.
• 3× daily: morning + mid-afternoon + pre-sleep, each ≥90 min from food.

Because the pulse is short, missing a dose does not accumulate — the research protocols in this library treat Ipamorelin as pulse-timed, not steady-state.

Ipamorelin arrives as a lyophilised (freeze-dried) white powder. Standard research reconstitution steps:

1. Confirm the vial label — mg mass, batch number, and matching HPLC CoA.
2. Wipe both vial stoppers (peptide vial + bacteriostatic water vial) with a fresh alcohol swab.
3. Draw the target BAC water volume — see the tables above for the concentration you want.
4. Inject the BAC water down the inside wall of the peptide vial, not directly onto the powder cake.
5. Swirl gently until fully dissolved. Do not shake — froth introduces oxidation and inaccurate draws.
6. Refrigerate immediately at 2–8 °C. Label the vial with reconstitution date.

Full method in the ultimate guide to peptide reconstitution and the bacteriostatic water guide. For dose conversions between vial sizes use the dose conversion calculator.

• Lyophilised, sealed: stable at 2–8 °C for the vendor-stated shelf life (usually 24+ months). Long-term at −20 °C is acceptable but not required.
• Reconstituted in BAC water: ~28 days refrigerated at 2–8 °C, protected from light.
• No freeze-thaw once reconstituted — ice-crystal formation damages peptide integrity.
• Discard early on cloudiness, precipitation or off colour.

Full method in the storage & stability guide.

Ipamorelin holds no MHRA marketing authorisation as a medicine in the UK. It is referenced as a laboratory-supply peptide for in vitro, cell-culture and animal research. It is not available on NHS or private prescription — clinical growth hormone deficiency in the UK is treated with recombinant human GH, not GHRP-mimetics.

Any UK-facing claim that Ipamorelin is a licensed pharmaceutical is inaccurate.

Dose accuracy is downstream of vial accuracy. A reference-grade Ipamorelin vial ships with a batch-specific certificate of analysis showing HPLC purity ≥98% and mass-spec identity confirmation. See the HPLC & CoA guide for how to read one.

UK researchers in this library reference peptidesuk4u.co.uk, which publishes lot-level HPLC CoAs alongside every Ipamorelin listing. For the full compound context see the Ipamorelin compound profile.